Elevai Labs Inc

Earnings data Q3 2024

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Elevai Labs, Inc. is a physician-dispensed skincare company, which engages in the research and development of skincare formulations. It is involved in the production and commercialization of topical skincare products that contain its proprietary stem cell-derived Elevai Exosomes. The company was founded by Hatem Abou-Sayed and Jordan R. Plews in 2020 and is headquartered in Newport Beach, CA.

Elevai Labs Inc. Subsidiary, Elevai Skincare Inc. Announces Encouraging Research Data Results Indicating Potential for Hair Restoration Using Proprietary

Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Encouraging Data Results Indicating Potential for Hair Restoration Using Proprietary Exosome Technology

Elevai Labs Inc. Files Combination Patents with Yuva Biosciences for Breakthrough Hair and Scalp Care Technology Utilizing YuvaBioⓇ Y100™ Mitochondria

Elevai Labs Inc. Files Combination Patents with Yuva Biosciences for Breakthrough Hair and Scalp Care Technology Utilizing YuvaBioⓇ Y100™ Mitochondrial Innovation and Elevai Exosomes™

NEWPORT BEACH, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a pioneering force in medical aesthetics, announces the completion of a clinical study examining the effectiveness of Elevai exosomes on facial appearance.

Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Data Results with Completion of Clinical Study of Elevai Enfinity™ Topical Exosome Serum

Preliminary data from the research study in partnership with Dalhousie University demonstrates that Elevai's hUMSC derived exosomes (“ELEVAI exosomes™”) contain over 800 proteins that are associated with wound healing, immunomodulation and remodeling of the skin's extracellular matrix (“ECM”). ELEVAI exosomes™ protein profile detected as part of this study was statistically significant and notably enriched compared to 54 previously published sets of exosome protein data.

Elevai Labs Inc. Subsidiary, Elevai Research Inc., Announces Preliminary Positive Research Data Highlighting the Potential of Proprietary Exosome Technology for Skin Health Applications

NEWPORT BEACH, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a pioneering force in medical aesthetics, today reported financial results for the second quarter ended June 30, 2024 and provided a business update.

Elevai Labs Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update

Professor of Medicine at the University of California, Los Angeles (UCLA), where he serves as Director of the UCLA Metabolism Research Theme. Over 180 publications in the field of obesity & metabolism, along with multiple NIH-funded projects as Principal Investigator.

Elevai Labs Inc. Subsidiary, Elevai Biosciences, Continues to Advance its Scientific Advisory Board with the Appointment of Orian Shirihai, MD, PhD

African Agriculture Holdings Inc

Estee Lauder

Moolec Science SA

The most oversold stocks in the consumer staples sector presents an opportunity to buy into undervalued companies. `

Top 4 Risk Off Stocks You'll Regret Missing In July

NEWPORT BEACH, Calif., June 14, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a pioneering force in medical aesthetics, announced the formation of a new Scientific Advisory Board to support the advancement of EL-22, a first-in-class engineered probiotic approach, to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists.

Elevai Labs Forms New Scientific Advisory Board for its Weight Loss Programs

NEWPORT BEACH, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a pioneering force in medical aesthetics, announced that Chief Executive Officer Dr. Jordan R.

Elevai Labs Inc Subsidiary, Elevai Biosciences, to Present at the UCLA LA-BEST 2024 Conference

NEWPORT BEACH, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a pioneering force in medical aesthetics, today reported financial results for the first quarter ended March 31, 2024.

Elevai Labs Inc. Reports First Quarter 2024 Financial Results

Preclinical results of EL-22 from a 2022 study demonstrated physiological (serum creatine kinase level), physical (body weight change), and functional (rotarod test) improvements in the dystrophic features of mdx mice, a mouse model of Duchenne muscular dystrophy (DMD)1. Elevai believes that EL-22 has the potential to treat obesity in combination with popular weight loss therapeutics, including GLP-1 receptor agonists, by preserving muscle mass while decreasing fat mass.

Elevai Biosciences Highlights Preclinical Data Showing Potential of In-Licensed Asset “EL-22” for The Treatment of Obesity

Elevai Labs Expands with Launch of Elevai Biosciences and Elevai Skincare Subsidiaries, Advancing the Future of Aesthetic Medicines and Exosome Skincare

Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments

Five international distribution agreements signed to date Cumulative contracted minimum purchase requirements of $4.9M in the first five years Up to five additional international distribution agreements in discussion NEWPORT BEACH, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- ELEVAI Labs Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a medical aesthetic company specializing in physician-dispensed skincare, announces significant strides in global distribution and highlights an overview of current agreements.

Elevai Labs Highlights Global Distribution Partnership Overview: Contracts May Secure $4.9M Top Line Revenue Commitments

Taiwan is ELEVAI's third Asian contract for exosomes distribution after adding the Philippines in August of 2023 and Vietnam in May 2023 Asia-Pacific represents a combined $13 Billion prestige skincare and luxury haircare market 4, 5 Immediate access to 40 specialty hair treatment clinics and four (4) high-end medical aesthetic clinics NEWPORT BEACH, Calif., April 22, 2024 (GLOBE NEWSWIRE) -- ELEVAI LABS, INC.

ELEVAI Labs Enters the Taiwan Market with Signing of 5th International Distribution Agreement in 14 Months

Company reports record annual revenues of $1.71 Million for 2023, up 123.5% over the previous year Company reports record Q4 2023 revenues of $698,591, up 403% from Q4 2022 NEWPORT BEACH, Calif., March 29, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ: ELAB), a medical aesthetic company specializing in physician-dispensed skincare, today reported financial results for the fourth quarter and full year ended December, 31, 2023.

Elevai Labs Inc. Reports Record Full Year 2023 and Fourth Quarter Financial Results

Elevai Labs Launches E-commerce Portal to Support Rapid Growth as Stem Cell Exosome Disruptor in the $19.7 Billion Global Physician Dispensed Cosmeceutical

Elevai Labs Launches E-commerce Portal to Support Rapid Growth as Stem Cell Exosome Disruptor in the $19.7 Billion Global Physician Dispensed Cosmeceutical Market

Elevai Labs (NASDAQ: ELAB ) stock is rocketing higher on Thursday as the skincare development company's shares experience heavy trading this morning. That has more than 9.4 million shares of ELAB stock changing hands of this writing.

Why Is Elevai Labs (ELAB) Stock Up 57% Today?

NEWPORT BEACH, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- ELEVAI LABS, INC.

ELEVAI Labs Inc. Announces Issuance of Patent from U.S. Patent & Trademark Office

Agriforce Growing Systems Ltd

Archer-Daniels-Midland Company

Webuy Global Ltd

The most oversold stocks in the consumer staples sector presents an opportunity to buy into undervalued companies.

Top 4 Defensive Stocks That Could Lead To Your Biggest Gains In January - AgriFORCE Growing Systems (NASDAQ:AGRI), Archer-Daniels Midland (NYSE:ADM)

ELEVAI Reports Strong Preliminary Unaudited Financial Performance for Fiscal Year 2023, Highlighting Significant Revenue Growth and Expanding Global Reach

ELEVAI LABS, Inc. Reports Strong Preliminary Unaudited Financial Performance for Fiscal Year 2023, Highlighting Significant Revenue Growth and Expanding Global Reach

Shares of medical aesthetics company Elevai Labs (NASDAQ: ELAB ) popped higher this morning following a key disclosure. Specifically, Elevai signed an exclusive, worldwide manufacturing and processing technology licensing agreement with INmune Bio (NASDAQ: INMB ) to manufacture stem cells.

Why Is Elevai Labs (ELAB) Stock Up Today?

NEWPORT BEACH, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (Nasdaq: ELAB) a medical aesthetic company specializing in physician-dispensed skincare is pleased to announce it has signed an exclusive, worldwide manufacturing and processing technology licensing agreement with INmune Bio, Inc., [Nasdaq: INMB].

ELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology

NEWPORT BEACH, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- ELEVAI LABS, INC.

ELEVAI LABS, Inc. to Participate in Upcoming Aesthetic Industry Conferences

Elevai Labs (NASDAQ: ELAB ) just reported results for the third quarter of 2024. Elevai Labs reported earnings per share of -7.8 cents.

News for Elevai Labs Inc Stock (ELAB)